This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poon, B.
Right arrow Articles by Grovit-Ferbas, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poon, B.
Right arrow Articles by Grovit-Ferbas, K.

 Previous Article  |  Next Article 

Journal of Virology, August 2005, p. 10210-10217, Vol. 79, No. 16
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.16.10210-10217.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Formaldehyde-Treated, Heat-Inactivated Virions with Increased Human Immunodeficiency Virus Type 1 Env Can Be Used To Induce High-Titer Neutralizing Antibody Responses

B. Poon,1,2,3 J. F. Hsu,1,3 V. Gudeman,1,3 I. S. Y. Chen,1,2,3 and K. Grovit-Ferbas1,3,4*

Departments of Medicine,1 Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA,2 UCLA AIDS Institute,3 Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California4

Received 3 January 2005/ Accepted 4 May 2005

The lack of success of subunit human immunodeficiency virus (HIV) type 1 vaccines to date suggests that multiple components or a complex virion structure may be required. We hypothesized that the failure of current vaccine strategies to induce protective antibodies is linked to the inability of native envelope structures to readily elicit these types of antibodies. We have previously reported on the ability of a formaldehyde-treated, heat-inactivated vaccine to induce modest antibody responses in animal vaccine models. We investigated here whether immunization for HIV with an envelope-modified, formaldehyde-stabilized, heat-inactivated virion vaccine could produce higher-titer and/or broader neutralizing antibody responses. Thus, a clade B vaccine which contains a single point mutation in gp41 (Y706C) that results in increased incorporation of oligomeric Env into virions was constructed. This vaccine was capable of inducing high-titer antibodies that could neutralize heterologous viruses, including those of clades A and C. These results further support the development of HIV vaccines with modifications in native Env structures for the induction of neutralizing antibody responses.

* Corresponding author. Mailing address: David Geffen School of Medicine at UCLA, 11-934 Factor Building, Los Angeles, CA 90095. Phone: (310) 268-4789. Fax: (310) 268-4532. E-mail: kferbas{at}ucla.edu.

Journal of Virology, August 2005, p. 10210-10217, Vol. 79, No. 16
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.16.10210-10217.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • An, D. S., Poon, B., Fang, R. H. T., Weijer, K., Blom, B., Spits, H., Chen, I. S. Y., Uittenbogaart, C. H. (2007). Use of a Novel Chimeric Mouse Model with a Functionally Active Human Immune System To Study Human Immunodeficiency Virus Type 1 Infection. CVI 14: 391-396 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»